Portal de Periódicos da CAPES

Estrogens in the Treatment of Prostate Cancer

1995; Lippincott Williams & Wilkins; Volume: 154; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(01)66670-9

1527-3792

Rebecca L. Cox, E. David Crawford,

Estrogen and related hormone effects

No AccessJournal of UrologyClinical Urology: Review Article1 Dec 1995Estrogens in the Treatment of Prostate Cancer R. Lee Cox and E. David Crawford R. Lee CoxR. Lee Cox and E. David CrawfordE. David Crawford View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)66670-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The history, mechanisms of action, efficacy and complications of estrogen therapy for prostate cancer are reviewed, and the current and future roles of estrogens in the treatment of prostate cancer are addressed. Materials and Methods: An extensive review of the literature was done. Results: Estrogens are effective in the treatment of advanced prostate cancer. High dose oral estrogens are associated with an increased risk of cardiovascular death. A dose of 1 mg. diethylstilbestrol daily is not associated with an increased risk of cardiovascular death. Estrogens are associated with other toxicities. Parenteral estrogens may not have the risk of cardiovascular death that is ascribed to oral estrogens. Estrogens have not been adequately compared to the combined androgen blockade regimen. Conclusions: A 1 mg. dose of diethylstilbestrol remains a medical alternative to bilateral orchiectomy in the treatment of advanced prostate cancer. Doses of 3 mg. diethylstilbestrol or more have a prohibitively high risk of cardiovascular death. Further studies comparing the efficacy, complications and cost of regimens containing oral estrogens or parenteral estrogens with agents that increase efficacy (for example antiandrogens) and decrease toxicity (for example anticoagulants) to results of other regimens, such as combined androgen blockade, should be done to determine if an estrogen-containing regimen could lower the cost of treating advanced prostate cancer. References 1 : Studies on prostatic cancer; effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of prostate.. Cancer Res.1941; 1: 293. Google Scholar 2 : Studies on prostatic cancer III. The effects of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate.. J. Urol.1941; 46: 997. Abstract, Google Scholar 3 : Studies on prostatic cancer; effects of castration on advanced carcinoma of prostate gland.. Arch. Surg.1941; 43: 209. Google Scholar 4 : Prostatic carcinoma, follow-up on 795 patients treated prior to endocrine era and comparison of survival rates between these and patients treated by endocrine therapy.. Surgery1946; 20: 263. Google Scholar 5 : Endocrine control of prostatic carcinoma, clinical and statistical survey of 1,818 cases.. J.A.M.A.1950; 143: 1317. Google Scholar 6 : Carcinoma of the prostate: treatment comparisons.. J. Urol.1967; 98: 516. Abstract, Google Scholar 7 : Treatment and survival of patients with cancer of the prostate.. Surg., Gynec. & Obst.1967; 124: 1011. Google Scholar 8 : Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo.. Cancer1970; 26: 257. Google Scholar 9 : the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate.. Cancer1973; 32: 1126. Google Scholar 10 : VACURG studies of conservative treatmentx. Scand. J. Urol. Nephrol., suppl.1980; 55: 99. Google Scholar 11 : Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.. Natl. Cancer Inst. Monogr.1988; 7: 165. Google Scholar 12 : Do we have a rational treatment plan for stage D-1 carcinoma of the prostate? World. J. Urol.1990; 8: 27. Google Scholar 13 : Lessons from phase III-trials on the hormonal treatment of prostatic carcinoma. I: results of EORTC-trials 30761 and 30762. In: EORTC Genitourinary Group Monograph 4: Management of Advanced Cancer of the Prostate and Bladder.. Edited by . New York: Alan R. Liss, Inc1988: 111. Google Scholar 14 : EORTC PROTOCOL 30805: a phase III trial comparing orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. In: EORTC Genitourinary Group Monograph 4: Management of Advanced Cancer of the Prostate and Bladder.. Edited by . New York: Alan R. Liss, Inc.1988: 101. Google Scholar 15 : Oestrogen dosage in prostatic cancer: the threshold effect.. Brit. J. Urol.1989; 64: 290. Google Scholar 16 : Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostate cancer. Finnprostate Group. Brit. J. Urol.1990; 66: 94. Google Scholar 17 : Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study. Scand. J. Urol. Nephrol.1994; 28: 171. Google Scholar 18 : Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer.. Brit. J. Urol.1991; 67: 184. Google Scholar 19 : Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma. Scand. J. Urol. Nephrol., suppl.1980; 55: 95. Google Scholar 20 : Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. J. Urol.1995; 153: 1580. Abstract, Google Scholar 21 : Preliminary report on the clinical use of TACE (chlorotrianisene) in treatment of prostatic carcinoma.. J. Urol.1951; 65: 886. Abstract, Google Scholar 22 : TACE in the treatment of carcinoma of the prostate: an 80-month survey.. J. Urol.1958; 80: 155. Abstract, Google Scholar 23 : The effects of cholorotrianisene (Tace) on kinetics of 3-H-testosterone metabolism in patients with carcinoma of the prostate.. Brit. J. Urol.1982; 54: 393. Google Scholar 24 : Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.. J. Urol.1992; 147: 931. Abstract, Google Scholar 25 : High-dose medroxprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study.. Brit. J. Urol.1991; 68: 67. Google Scholar 26 : Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate.. Urology1987; 29: 55. Google Scholar 27 : Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt).. Scand. J. Urol. Nephrol.1977; 11: 231. Google Scholar 28 : Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate. Scand. J. Urol. Nephrol., suppl.1980; 55: 139. Google Scholar 29 : Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.. J. Cell. Biol.1988; 107: 2647. Google Scholar 30 : Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate.. J. Urol.1981; 125: 664. Abstract, Google Scholar 31 : Treatment preferences of urologists in Great Britain and Ireland in the management of prostate cancer.. Brit. J. Urol.1993; 71: 577. Google Scholar 32 : Plasma testosterone in patients receiving diethylstilbestrol.. Urology1978; 11: 157. Google Scholar 33 : Testicular endocrine function after withdrawal of oestrogen treatment in patients with carcinoma of the prostate.. Brit. J. Urol.1983; 55: 42. Google Scholar 34 : Hormonal effects of cessation of estrogen treatment for prostatic carcinoma.. J. Urol.1987; 138: 801. Abstract, Google Scholar 35 : Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma.. Brit. Med. J.1971; 4: 391. Google Scholar 36 : Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma.. J. Urol.1973; 109: 858. Abstract, Google Scholar 37 : Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer.. Brit. J. Urol.1973; 45: 668. Google Scholar 38 : A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.. J. Urol.1984; 131: 1107. Abstract, Google Scholar 39 : The Leuprolide Study Group. New Engl. J. Med.1984; 311: 1281. Google Scholar 40 : Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J. Urol.1990; 143: 68. Link, Google Scholar 41 : Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology, suppl.1989; 33: 45. Google Scholar 42 : Relapse on endocrine treatment in patients with stage D2 prostate cancer.. Does second-line hormonal therapy affect survival? Urology1993; 41: 144. Google Scholar 43 : Estrogen treatment postpones the castration-induced dedifferentiation of Dunning R3327-PAP prostatic adenocarcinoma.. Prostate1994; 25: 10. Google Scholar 44 : Effects of synthetic oral oestrogens in normal men and patients with prostatic carcinoma: lack of gonadotrophin suppression by chlorotrianisene.. Clin. Endocr.1973; 2: 297. Google Scholar 45 : The time for serum testosterone to castrate level after bilateral orchiectomy or oral estrogen therapy in the management of prostatic cancer. J. Urol.1994; 151: 238A. abstract 41. Google Scholar 46 : Long-term effects of endocrine treatment on serum pituitary hormones in advanced prostatic carcinoma patients.. Scand. J. Urol. Nephrol.1981; 15: 207. Google Scholar 47 : Comparison of various hormonal therapies for prostatic carcinoma. Sem. Oncol., suppl.1983; 10: 34. Google Scholar 48 : Androgens during different modes of endocrine treatment of prostatic cancer.. Urol. Res.1989; 17: 95. Google Scholar 49 : Regression of prostatic cancer metastasis by high doses of diethylstilbestrol diphosphate.. Urology1976; 7: 598. Google Scholar 50 : Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--a randomized study: results after 7 to 10 years of followup.. J. Urol.1991; 145: 519. Abstract, Google Scholar 51 : Plasma hormones levels in patients with prostatic carcinoma treated with diethylstilbestrol and estramustine.. Brit. J. Urol.1985; 57: 542. Google Scholar 52 : Cardiovascular complications in the treatment of prostatic carcinoma.. Brit. J. Urol.1981; 53: 624. Google Scholar 53 : Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients. Scand, J. Urol. Nephrol., suppl.1980; 55: 103. Google Scholar 54 : Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate.. Cancer1970; 26: 249. Google Scholar 55 : Some effects of treatment with ethinyl oestradiol with or without polyoestradiol phosphate in patients with prostatic carcinoma.. Scand. J. Urol. Nephrol.1986; 20: 193. Google Scholar 56 : Oral stilboestrol diphosphate ("Honvan") in the treatment of prostatic carcinoma: a clinical trial.. Brit. J. Urol.1967; 39: 147. Google Scholar 57 : The choice of estrogen preparations in the treatment of prostatic cancer.. Canad. Med. Ass. J.1975; 113: 865. Google Scholar 58 : Oestrogen in the treatment of prostatic carcinoma. What is the safe and effective dose of ethinyloestradiol? Brit.. J. Urol.1989; 63: 76. Google Scholar 59 : Single drug polyestradiol phosphate therapy in prostatic cancer. Amer. J. Clin. Oncol.1988; : S101. Google Scholar 60 : Oestrogen therapy in prostatic cancer. Scand. J. Urol. Nephrol., suppl.1980; 55: 91. Google Scholar 61 : Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.. J. Clin. Oncol.1990; 8: 1675. Google Scholar 62 : Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up of a national prospective prostatic cancer study. Brit. J. Urol.1986; 58: 528. Google Scholar 63 : The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.. J. Urol.1988; 140: 1460. Abstract, Google Scholar 64 : Medical castration of males with megestrol acetate and small doses of diethylstilbestrol.. J. Clin. Endocr. Metab.1981; 52: 576. Google Scholar 65 : Treatment of advanced cancer of prostate with megestrol acetate.. Urology1978; 12: 537. Google Scholar 66 : A cooperative group study of prostatic cancer: stilbestrol versus placebo in advanced progressive disease.. Cancer Chemother. Rep.1962; 16: 323. Google Scholar 67 : The diagnosis of oestrogen escape and the role of secondary orchiectomy in prostatic cancer.. Brit. J. Urol.1980; 52: 535. Google Scholar 68 : Prostatic carcinoma: treatment of advanced cases with intravenous diethylstilbestrol diphosphate.. J. Urol.1955; 74: 549. Abstract, Google Scholar 69 : Stilphostrol therapy in 100 cases of prostatic carcinoma.. J. Iowa Med. Soc.1969; 59: 1096. Google Scholar 70 : High-dose diethylstilbestrol diphosphate therapy of prostatic cancer after failure of standard doses of estrogens.. Canad. Med. Ass. J.1973; 109: 697. Google Scholar 71 : A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer.. Cancer1985; 56: 457. Google Scholar 72 : Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate.. J. Urol.1985; 133: 620. Abstract, Google Scholar 73 : Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone.. Urology1992; 39: 108. Google Scholar 74 : Megestrol acetate for the prevention of hot flashes.. New Engl. J. Med.1994; 331: 347. Google Scholar 75 : Treatment of radiation or cyclophosphamide induced hemorrhagic cystitis using conjugated estrogen.. J. Urol.1990; 144: 41. Abstract, Google Scholar 76 : Control of massive hematuria in idiopathic hemorrhagic cystitis after administration of conjugated estrogen.. J. Urol.1992; 148: 1524. Abstract, Google Scholar 77 : Treatment of uraemic bleeding with conjugated oestrogen.. Lancet1984; 2: 887. Google Scholar 78 : Conjugated estrogens for the management of bleeding associated with renal failure.. New Engl. J. Med.1986; 315: 731. Google Scholar 79 : Oral estrogens decrease bleeding time and improve clinical bleeding in patients with renal failure.. Amer. J. Med.1990; 89: 436. Google Scholar 80 : Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. Urology, suppl.1994; 43: 61. Google Scholar 81 : Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate. Urology, suppl.1994; 43: 57. Google Scholar 82 : A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area.. J. Urol.1983; 129: 56. Abstract, Google Scholar 83 : Estramustine phosphate versus placebo in hormone refractory prostate cancer. Danish Prostatic Cancer Group study 9002. J. Urol.1995; 153: 239A. abstract 41. Google Scholar 84 : The combination of estramustine and etopside is an active oral regimen for the treatment of patients with hormone refractory prostate cancer: report of a phase II trial. J. Urol.1995; 153: 239A. abstract 43. Google Scholar 85 : Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.. Brit. Med. J.1986; 293: 413. Google Scholar 86 : Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer.. Brit. J. Urol.1989; 63: 186. Google Scholar 87 : Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.. Prostate1991; 18: 131. Google Scholar 88 : High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate group.. Brit. J. Urol.1989; 63: 512. Google Scholar 89 : Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients.. Eur. Urol.1990; 17: 229. Google Scholar 90 : Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma.. Brit. J. Urol.1990; 65: 282. Google Scholar 91 : Sexual function in prostatic cancer patients treated with radiotherapy, orchiectomy or oestrogens.. Brit. J. Urol.1984; 56: 64. Google Scholar 92 : Oestrogens reconsidered.. Sem. Surg. Oncol.1995; 11: 72. Google Scholar 93 : Cancer statistics, 1994.. CA1994; 44: 7. Google Scholar 94 : A controlled trial of leuprolide with and without flutamide in prostatic cancer.. New Engl. J. Med.1989; 321: 419. Google Scholar 95 : Carcinoma of the prostate. In: . Philadelphia: W. B. Saunders Co.1986: 1463. chapt. 32. Google Scholar 96 : Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma.. Brit. J. Urol.1990; 65: 282. Google Scholar Division of Urology, Department of Surgery, School of Medicine, University of Colorado Health Sciences Center, Denver, Colorado.© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byBennett J, Foote J, Alphonse P and Hood N (2018) Re: Obesity and Prostate Cancer: Importance of Race and Stage of DiseaseJournal of Urology, VOL. 179, NO. 6, (2481-2482), Online publication date: 1-Jun-2008.Pitts W (2018) RE: OSTEOPOROSIS AND SPINAL FRACTURES IN MEN WITH PROSTATE CANCER: RISK FACTORS AND EFFECTS OF ANDROGEN DEPRIVATION THERAPYJournal of Urology, VOL. 173, NO. 5, (1829-1829), Online publication date: 1-May-2005. (2018) RE: OSTEOPOROSIS AND SPINAL FRACTURES IN MEN WITH PROSTATE CANCER: RISK FACTORS AND EFFECTS OF ANDROGEN DEPRIVATION THERAPYJournal of Urology, VOL. 173, NO. 5, (1829-1830), Online publication date: 1-May-2005.OCKRIM J, LALANI E, KAKKAR A and ABEL P (2018) TRANSDERMAL ESTRADIOL THERAPY FOR PROSTATE CANCER REDUCES THROMBOPHILIC ACTIVATION AND PROTECTS AGAINST THROMBOEMBOLISMJournal of Urology, VOL. 174, NO. 2, (527-533), Online publication date: 1-Aug-2005.Penson D, Moul J, Evans C, Doyle J, Gandhi S and Lamerato L (2018) RE: THE ECONOMIC BURDEN OF METASTATIC AND PROSTATE SPECIFIC ANTIGEN PROGRESSION IN PATIENTS WITH PROSTATE CANCER: FINDINGS FROM A RETROSPECTIVE ANALYSIS OF HEALTH PLAN DATAJournal of Urology, VOL. 172, NO. 6 Part 1, (2484-2484), Online publication date: 1-Dec-2004. (2018) Re: Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate CancerJournal of Urology, VOL. 170, NO. 6, (2392-2394), Online publication date: 1-Dec-2003. (2018) Re: Enhancement of Diethylstilbestrol Induced Cytotoxicity by bcl-2 Antisense Oligodeoxynucleotides and a Glutathione Depletor for Prostate Cancer: Reply by AuthorsJournal of Urology, VOL. 170, NO. 5, (1954-1955), Online publication date: 1-Nov-2003.SCHERR D and PITTS W (2018) The Nonsteroidal Effects of Diethylstilbestrol: The Rationale for Androgen Deprivation Therapy Without Estrogen Deprivation in the Treatment of Prostate CancerJournal of Urology, VOL. 170, NO. 5, (1703-1708), Online publication date: 1-Nov-2003.Pitts W (2018) Re: Enhancement of Diethylstilbestrol Induced Cytotoxicity by bcl-2 Antisense Oligodeoxynucleotides and a Glutathione Depletor for Prostate CancerJournal of Urology, VOL. 170, NO. 5, (1954-1954), Online publication date: 1-Nov-2003.Pitts W (2018) Re: Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate CancerJournal of Urology, VOL. 170, NO. 6, (2392-2393), Online publication date: 1-Dec-2003.SCHERR D, PITTS W and VAUGHAN E (2018) DIETHYLSTILBESTEROL REVISITED: ANDROGEN DEPRIVATION, OSTEOPOROSIS AND PROSTATE CANCERJournal of Urology, VOL. 167, NO. 2 Part 1, (535-538), Online publication date: 1-Feb-2002.Pitts W (2018) RE: EDITORIAL COMMENT: RE: DIETHYLSTILBESTEROL REVISITED: ANDROGEN DEPRIVATION, OSTEOPOROSIS AND PROSTATE CANCERJournal of Urology, VOL. 168, NO. 5, (2131-2131), Online publication date: 1-Nov-2002.Pitts W (2018) RE: DIETHYLSTILBESTEROL REVISITED: ANDROGEN DEPRIVATION, OSTEOPOROSIS AND PROSTATE CANCERJournal of Urology, VOL. 168, NO. 1, (201-201), Online publication date: 1-Jul-2002.SPETZ A, HAMMAR M, LINDBERG B, SPÅNGBERG A and VARENHORST E (2018) PROSPECTIVE EVALUATION OF HOT FLASHES DURING TREATMENT WITH PARENTERAL ESTROGEN OR COMPLETE ANDROGEN ABLATION FOR METASTATIC CARCINOMA OF THE PROSTATEJournal of Urology, VOL. 166, NO. 2, (517-520), Online publication date: 1-Aug-2001.Walther M and Pitts W (2018) RE: MEDICAL VERSUS SURGICAL ANDROGEN SUPPRESSION THERAPY FOR PROSTATE CANCER: A 10-YEAR LONGITUDINAL COST STUDYJournal of Urology, VOL. 166, NO. 2, (632-632), Online publication date: 1-Aug-2001.MARIANI A, GLOVER M and ARITA S (2018) MEDICAL VERSUS SURGICAL ANDROGEN SUPRESSION THERAPY FOR PROSTATE CANCER: A 10-YEAR LONGITUDINAL COST STUDYJournal of Urology, VOL. 165, NO. 1, (104-107), Online publication date: 1-Jan-2001.MOUL J (2018) PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCERJournal of Urology, VOL. 163, NO. 6, (1632-1642), Online publication date: 1-Jun-2000.TARIQ N, JENKINS D, VIDGEN E, FLESHNER N, KENDALL C, STORY J, SINGER W, D'COSTA M and STRUTHERS N (2018) EFFECT OF SOLUBLE AND INSOLUBLE FIBER DIETS ON SERUM PROSTATE SPECIFIC ANTIGEN IN MENJournal of Urology, VOL. 163, NO. 1, (114-118), Online publication date: 1-Jan-2000.Pavlovich C and Pitts W (2018) RE: OSTEOPOROSIS AFTER ORCHIECTOMY FOR PROSTATE CANCERJournal of Urology, VOL. 162, NO. 4, (1392-1392), Online publication date: 1-Oct-1999.WASSON J, FOWLER F and BARRY M (2018) ANDROGEN DEPRIVATION THERAPY FOR ASYMPTOMATIC ADVANCED PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN ERA: A NATIONAL SURVEY OF UROLOGIST BELIEFS AND PRACTICESJournal of Urology, VOL. 159, NO. 6, (1993-1997), Online publication date: 1-Jun-1998. Volume 154Issue 6December 1995Page: 1991-1998 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information R. Lee Cox More articles by this author E. David Crawford More articles by this author Expand All Advertisement PDF downloadLoading ...